Product Images Metformin Hydrochloride

This text provides a summary table of lipid changes from baseline of a 24-week study in patients on various dosages of Metformin Hydrochloride Tablets, Extended Release. The changes in Total Cholesterol, Total Triglycerides, LDL-Cholesterol, and HDL-Cholesterol are reported along with the baseline measurements and mean percent changes at the final visit for each dosage group.*

The text describes a table presenting the summary of mean percent change of serum lipid variables in different treatments for 29-week studies using Metformin Hydrochloride tablets, Glyburide or a combination of both. The table reports the baseline levels and the mean % change from the baseline of Total Cholesterol, Total Triglycerides, LDL-Cholesterol, and HDL-Cholesterol in each treatment approach.*

This is a description of a medication called Metformin 850mg. The medication comes in #30 tablets and each tablet contains Metformin Hydrochloride, USP 850mg. The tablets are white to off-white, round, and biconvex with "H/103" debossed on one side and plain on the other side. The product is manufactured in India and packaged by Proficient Rx LP. The lot number is 00000 and the expiration date is 00/00/00. It is RX only and should be stored at 20°-25°C (68°-77°F). The medication should be kept out of reach of children. The NDC is 71205-142-30 and the product ID is QM014230.*

This text provides some basic statistics about a group of pediatric patients who were all on a diet therapy at the beginning of the study. The mean age of the patients was 13.8 years, with a range of 10 to 16 years. The note indicates that there was no statistical significance found in the data.*

This is a summary of the mean differences from the baseline in fasting plasma glucose, hemoglobin, and body weight between patients who took metformin hydrochloride tablets and those who took a placebo during a 29-week study. The data suggests that Metformin Hydrochloride Tablets significantly reduced fasting plasma glucose and hemoglobin A levels compared to placebo, but had no significant effect on body weight. However, the difference in baseline body weight between the two groups was small, and not statistically significant. All patients were on diet therapy at baseline.*

The table compares the effectiveness of Metformin Hydrochloride Tablets versus Placebo in reducing plasma glucose and body weight in pediatric patients. The table displays a summary of mean changes from baseline to final visit for both groups. Metformin Hydrochloride Tablets were found to be significantly more effective in reducing plasma glucose levels compared to Placebo. However, there was no significant difference in body weight reduction between the two groups.*

This is a table summarizing the results of a 23-week study comparing the effects of combining Metformin Hydrochloride Tablets/Glyburide to Glyburide or Metformin Hydrochloride Tablets alone. The table reflects the mean changes from baseline in fasting plasma glucose, HbA, and body weight at the final visit for all three treatments. There are p-values for comparison between Glyburide vs Metformin Hydrochloride Tablets, Glyburide vs the combination, and Metformin Hydrochloride Tablets vs the combination. Not statistically significant results are marked as NS.*

The table provides a comparison of the mean changes from the baseline in Hemoglobin A and Daily Insulin Dose for patients who took combined Metformin Hydrochloride Tablets/Insulin and Placebo Insulin. The data shows that the treatment with Metformin Hydrochloride Tablets/Insulin resulted in a significant reduction in Hemoglobin A levels compared to the Placebo Insulin. The insulin dosage did not show any significant difference between the two groups.*